Share on StockTwits

Investment analysts at Wells Fargo & Co. assumed coverage on shares of Immune Design Corp (NASDAQ:IMDZ) in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.

Separately, analysts at Jefferies Group initiated coverage on shares of Immune Design Corp in a research note on Monday. They set a “buy” rating and a $15.00 price target on the stock.

Immune Design Corp (NASDAQ:IMDZ) opened at 12.41 on Monday. Immune Design Corp has a 52-week low of $11.51 and a 52-week high of $12.81. The stock has a 50-day moving average of $12.12 and a 200-day moving average of $12.12. The company’s market cap is $195.7 million.

Immune Design Corp is a clinical-stage immunotherapy company. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (NASDAQ:IMDZ), to fight cancer.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.